This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View
by Zacks Equity Research
Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.
Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
Integra (IART) Reports In-Line Q2 Earnings, Tapers View
by Zacks Equity Research
Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.
Varian Medical (VAR) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Varian Medical (VAR) see strong growth in Oncology Systems. Solid guidance boosts investors' optimism.
AbbVie Secures FDA Approval for Endometriosis Drug Elagolix
by Zacks Equity Research
AbbVie (ABBV) gains an FDA approval for its late-stage pipeline candidate, Orilissa, for the treatment of moderate to severe pain associated with endometriosis in women.
Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View
by Zacks Equity Research
Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.
What's in the Cards for CVS Health (CVS) in Q2 Earnings?
by Zacks Equity Research
CVS Health (CVS) is optimistic about living up to its strong earnings surprise history year over year in Q2 as well, courtesy of gains from the Pharmacy Services segment.
LabCorp (LH) Tops on Q2 Earnings & Revenues, Narrows '18 View
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development business has reported sturdy growth on strategic acquisitions, robust organic growth and a positive foreign currency translation.
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
by Swarup Gupta
Biotech stocks are largely resilient to trade related disruptions.
AstraZeneca Sells Atacand's European Rights to Cheplapharm
by Zacks Equity Research
AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.
Allergan's Depression Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.
Can Solid Overall Growth Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) to gain from strong revenues at the Product, Service and other segments in Q2.
Invest in 5 Mega Trends to Overcome Trade War Jitters
by Tirthankar Chakraborty
Companies involved in artificial intelligence, e-commerce, mobile payments, biotechnology and gaming are unperturbed by escalated trade war tensions. We share a few solid stocks from such spaces so that you can trade them.
Karyopharm Initiates NDA Submission Process for Selinexor
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
by Zacks Equity Research
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
Roche's Tecentriq Gets Breakthrough Therapy Status for HCC
by Zacks Equity Research
The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.
J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
J&J's (JNJ) Phase III Study for Invokana Halted Earlier
by Zacks Equity Research
Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.
J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Zacks.com featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina
4 Best Efficient Stocks to Add to Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
BioTime (BTX) in Focus: Stock Moves 7.3% Higher
by Zacks Equity Research
BioTime (BTX) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Why Aptose Biosciences (APTO) Could Be Positioned for a Slump
by Zacks Equity Research
Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.